Eli Lilly has partnered with Chai Discovery to use the Chai-2 algorithm for antibody design, followi...
The AMW Read
Updates the player map for specialized biological architectures in Vertical AI-Bio, illustrating the trend of incumbents (Eli Lilly) integrating specialized foundation models for drug discovery.
NoveltySignificance
Healthcare & Bio · Player Map
Eli Lilly has partnered with Chai Discovery to use the Chai-2 algorithm for antibody design, following Chai's 130 million dollar Series B at a 1.3 billion dollar valuation. This collaboration integrates custom proteomics with Lilly's 1 billion dollar Nvidia-backed lab, replacing generic models with specialized biological architectures. This systemic shift toward proprietary AI toolkits aims to move first-in-class medicines into clinical trials by late 2027. 🧬💻🚀
